Article info

Download PDFPDF

Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Authors

  1. a ghayabhaya{at}aol.com
  2. b kimse{at}karmanos.org
  3. c bumman{at}karmanos.org
  4. d landryc{at}karmanos.org
  5. e silskic{at}karmanos.org
  6. f suishams{at}karmanos.org
  7. g dickowb{at}karmanos.org
  8. h heathe{at}karmanos.org
  9. i fontanaj{at}karmanos.org
  10. j 313-576-8715 vaishamu{at}karmanos.org
View Full Text

Citation

Jeyakumar G, Kim S, Bumma N, et al
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Publication history

  • Received July 11, 2017
  • Accepted October 3, 2017
  • First published October 17, 2017.
Online issue publication 
October 17, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.